{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:57:38Z","timestamp":1761339458693},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s40258-015-0162-9","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T08:24:14Z","timestamp":1426062254000},"page":"369-379","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin\/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis"],"prefix":"10.1007","volume":"13","author":[{"given":"Santiago","family":"Grau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Valladares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Cavanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Nocea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"162_CR1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/archsurg.1996.01430230075014","volume":"131","author":"NV Christou","year":"1996","unstructured":"Christou NV, Turgeon P, Wassef R, et al. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg. 1996;131:1193\u2013201.","journal-title":"Arch Surg."},{"issue":"11\u201312","key":"162_CR2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/00365540701449377","volume":"39","author":"JM Tellado","year":"2007","unstructured":"Tellado JM, Sen SS, Caloto MT, et al. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scand J Infect Dis. 2007;39(11\u201312):947\u201355.","journal-title":"Scand J Infect Dis."},{"issue":"2","key":"162_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133\u201364.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"162_CR4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ciresp.2009.09.014","volume":"87","author":"X Guirao","year":"2010","unstructured":"Guirao X, Arias J, Bad\u00eda JM, Garc\u00eda-Rodr\u00edguez JA, Mensa J, Alvarez-Lerma F, et al. Recommendations in the empiric anti-infective agents of intra-abdominal infection. Cir Esp. 2010;87(2):63\u201381.","journal-title":"Cir Esp."},{"issue":"3","key":"162_CR5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","volume":"5","author":"A Gin","year":"2007","unstructured":"Gin A, Dilay L, Karlowsky JA, et al. Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5(3):365\u201383.","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"2","key":"162_CR6","first-page":"235","volume":"237","author":"JS Solomkin","year":"2003","unstructured":"Solomkin JS, Yellin AE, Rotstein OD, Protocol 017 Study Group, et al. Ertapenem versus piperacillin\/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg. 2003;237(2):235\u201345.","journal-title":"Ann Surg."},{"issue":"4","key":"162_CR7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/sur.2009.057","volume":"11","author":"SP Hawser","year":"2010","unstructured":"Hawser SP, Bouchillon SK, Hoban DJ, et al. Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002\u20132007 from the SMART study. Surg Infect (Larchmt). 2010;11(4):371\u20138.","journal-title":"Surg Infect (Larchmt)."},{"issue":"4","key":"162_CR8","first-page":"223","volume":"24","author":"R Cant\u00f3n","year":"2011","unstructured":"Cant\u00f3n R, Loza E, Aznar J, SMART-Spain Working Group, et al. Antimicrobial susceptibility of Gram-negative organisms from intra-abdominal infections and evolution of isolates with extended spectrum \u03b2-lactamases in the SMART study in Spain (2002\u20132010). Rev Esp Quimioter. 2011;24(4):223\u201332.","journal-title":"Rev Esp Quimioter."},{"issue":"2","key":"162_CR9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/sur.2011.048","volume":"13","author":"N Qvist","year":"2012","unstructured":"Qvist N, Warren B, Leister-Tebbe H, et al. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect (Larchmt). 2012;13(2):102\u20139.","journal-title":"Surg Infect (Larchmt)."},{"issue":"12","key":"162_CR10","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cis270","volume":"54","author":"P Prasad","year":"2012","unstructured":"Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on non-inferiority trials. Clin Infect Dis. 2012;54(12):1699\u2013709.","journal-title":"Clin Infect Dis."},{"key":"162_CR11","unstructured":"EMA. Questions and answers on the review of Tygacil (tigecycline). Outcome of a renewal procedure. 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/human\/000644\/WC500102228.pdf . Accessed 25 June 2013."},{"key":"162_CR12","unstructured":"FDA. Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm224370.htm . Accessed 25 June 2013."},{"issue":"1","key":"162_CR13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00019053-200119010-00006","volume":"19","author":"ES Dietrich","year":"2001","unstructured":"Dietrich ES, Schubert B, Ebner W, et al. Cost efficacy of tazobactam\/piperacillin versus imipenem\/cilastatin in the treatment of intra-abdominal infection. Pharmacoeconomics. 2001;19(1):79\u201394.","journal-title":"Pharmacoeconomics."},{"issue":"3","key":"162_CR14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.diagmicrobio.2009.10.018","volume":"66","author":"F Tubau","year":"2010","unstructured":"Tubau F, Li\u00f1ares J, Rodr\u00edguez MD, et al. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery. Diagn Microbiol Infect Dis. 2010;66(3):308\u201313.","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"4","key":"162_CR15","first-page":"395","volume":"20","author":"M Gobernado","year":"2007","unstructured":"Gobernado M, Sanz-Rodr\u00edguez C, Villanueva R, et al. In vitro activity of ertapenem against clinical bacterial isolates in 69 Spanish medical centers (E-test study). Rev Esp Quimioter. 2007;20(4):395\u2013408.","journal-title":"Rev Esp Quimioter."},{"issue":"2","key":"162_CR16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.diagmicrobio.2012.05.032","volume":"74","author":"D Mayne","year":"2012","unstructured":"Mayne D, Dowzicky MJ. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004\u20132009). Diagn Microbiol Infect Dis. 2012;74(2):151\u20137.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"162_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2334-10-72","volume":"10","author":"ML Joly-Guillou","year":"2010","unstructured":"Joly-Guillou ML, Kempf M, Cavallo JD, et al. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin\/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis. 2010;10:72.","journal-title":"BMC Infect Dis."},{"issue":"5","key":"162_CR18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1157\/13120413","volume":"26","author":"O Cuevas","year":"2008","unstructured":"Cuevas O, Cercenado E, Goyanes MJ, et al. Staphylococcus spp. in Spain: present situation and evolution of antimicrobial resistance (1986\u20132006) [in Spanish]. Enferm Infecc Microbiol Clin. 2008;26(5):269\u201377.","journal-title":"Enferm Infecc Microbiol Clin."},{"issue":"1","key":"162_CR19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.anaerobe.2011.12.022","volume":"18","author":"M Trevi\u00f1o","year":"2012","unstructured":"Trevi\u00f1o M, Areses P, Pe\u00f1alver MD, et al. Susceptibility trends of Bacteroides fragilis group and characterization of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. Anaerobe. 2012;18(1):37\u201343.","journal-title":"Anaerobe."},{"issue":"11","key":"162_CR20","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkq321","volume":"65","author":"H Seifert","year":"2010","unstructured":"Seifert H, Dalhoff A, PRISMA Study Group. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother. 2010;65(11):2405\u201310.","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"162_CR21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1524-4733.2008.00439.x","volume":"12","author":"JP Jansen","year":"2009","unstructured":"Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin\/tazobactam in the treatment of complicated intra-abdominal infections accounting for antibiotic resistance. Value Health. 2009;12(2):234\u201344.","journal-title":"Value Health."},{"issue":"12","key":"162_CR22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2165\/11310080-000000000-00000","volume":"27","author":"JP Jansen","year":"2009","unstructured":"Jansen JP, Kumar R, Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin\/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics. 2009;27(12):1045\u201356.","journal-title":"Pharmacoeconomics."},{"issue":"9","key":"162_CR23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10096-004-1199-0","volume":"23","author":"K Krobot","year":"2004","unstructured":"Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2004;23(9):682\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"162_CR24","doi-asserted-by":"crossref","unstructured":"Sauerland S, Lefering R, Neugebauer EAM. Laparoscopic versus open surgery for suspected appendicitis. Cochrane Database Syst Rev. 2004;(4):CD001546. doi: 10.1002\/14651858.CD001546.pub2 .","DOI":"10.1002\/14651858.CD001546.pub2"},{"key":"162_CR25","unstructured":"Spanish Ministry of Health, Social Policy and Equality, Institute for Health Information. CMBD Minimum Basis Data Set. 2011. http:\/\/pestadistico.msc.es . Accessed 25 June 2013."},{"key":"162_CR26","unstructured":"Spanish Ministry of Health, Social Policy and Equality. Institute for Health Information. Diagnosis Related Group costs in Spain. http:\/\/www.msssi.gob.es\/estadEstudios\/estadisticas\/docs\/SNS2011_PESOS_COSTES_AP27_DEF.pdf . Accessed 25 June 2013."},{"key":"162_CR27","unstructured":"Spanish General Council of Official Colleges of Pharmacists. Bot PLUS 2.0. https:\/\/botplusweb.portalfarma.com\/ . Accessed 25 June 2013."},{"key":"162_CR28","unstructured":"Royal decree-law 8\/2010, of May 20, on extraordinary measures to reduce Government deficit (RDL 8\/2010). http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf . Accessed 25 June 2013."},{"issue":"9","key":"162_CR29","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1128\/JCM.00580-11","volume":"49","author":"GV Doern","year":"2011","unstructured":"Doern GV, Brecher SM. The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests. J Clin Microbiol. 2011;49(9):S11\u20134.","journal-title":"J Clin Microbiol."},{"issue":"9","key":"162_CR30","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1086\/507288","volume":"27","author":"CM Fortaleza","year":"2006","unstructured":"Fortaleza CM, Freire MP, FilhoDde C, et al. Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol. 2006;27(9):901\u20136.","journal-title":"Infect Control Hosp Epidemiol."},{"issue":"12","key":"162_CR31","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00064-09","volume":"53","author":"EJ Goldstein","year":"2009","unstructured":"Goldstein EJ, Citron DM, Peraino V, et al. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(12):5122\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"162_CR32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10096-005-1356-0","volume":"24","author":"MJ Dinubile","year":"2005","unstructured":"Dinubile MJ, Friedland I, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis. 2005;24(7):443\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"Suppl 4","key":"162_CR33","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1086\/314079","volume":"31","author":"MH Kollef","year":"2000","unstructured":"Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31(Suppl 4):S131\u20138.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"162_CR34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1524-4733.2009.00680.x","volume":"13","author":"AJ S\u00e1ez-Castillo","year":"2010","unstructured":"S\u00e1ez-Castillo AJ, Olmo-Jim\u00e9nez MJ, P\u00e9rez S\u00e1nchez JM, et al. Bayesian analysis of nosocomial infection risk and length of stay in a department of general and digestive surgery. Value Health. 2010;13(4):431\u20139.","journal-title":"Value Health."},{"issue":"1","key":"162_CR35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archsurg.136.1.55","volume":"136","author":"T Koperna","year":"2001","unstructured":"Koperna T, Semmler D, Marian F. Risk stratification in emergency surgical patients: is the APACHE II score a reliable marker of physiological impairment? Arch Surg. 2001;136(1):55\u20139.","journal-title":"Arch Surg."},{"issue":"1","key":"162_CR36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/sur.2006.030","volume":"8","author":"N Namias","year":"2007","unstructured":"Namias N, Solomkin JS, Jensen EH, et al. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin\/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt). 2007;8(1):15\u201328.","journal-title":"Surg Infect (Larchmt)."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-015-0162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-015-0162-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-015-0162-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:41Z","timestamp":1559503721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-015-0162-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1007\/s40258-015-0162-9","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}